Overview
Clinical Benefits
- Reduces visceral abdominal fat
- Increases IGF-1 levels
- Improves body composition
- Enhances cognitive function
- Potential neuroprotective effects
Administration
Subcutaneous injection — abdomen, rotate injection sites
Drug class: ghrh analog
Clinical Dosing
Typical dosage
1-2mg daily
Starting dose
1mg
Cadence
Once daily
Full titration schedule
| Phase | Dose |
|---|---|
| Weeks 1-2 | 1mg once daily |
| Weeks 3-4 | 1.5mg once daily (if well-tolerated) |
| Weeks 5+ | 2mg once daily (maintenance) |
Safety Profile
Side effects
- • Injection site reactions
- • Joint pain
- • Peripheral edema
- • Muscle pain
- • Paresthesia
Contraindications
- • Active malignancy
- • Hypersensitivity to tesamorelin or mannitol
- • Pregnancy
- • Disruption of hypothalamic-pituitary axis
Featured in these stacks
Frequently asked questions
Tesamorelin is most commonly researched for: Reduces visceral abdominal fat, Increases IGF-1 levels, Improves body composition, Enhances cognitive function.
Ready to build a protocol with Tesamorelin?
LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.
You’ll be asked to sign in first. Free tier includes the chat preview.
Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.